Dopamine D1 Receptor Agonists
作者： R Jeroen Vermeulen , Benjamin Drukarch , Erik C. Wolters , Johannes C. Stoof
DOI: 10.2165/00023210-199911020-00001
关键词:
摘要: The pharmacotherapy of Parkinson’s disease mainly consists treatment with levodopa and/or dopamine receptor agonists, which compensate for the loss in CNS that characterises disease. Although is more effective than former frequently causes serious adverse effects, e.g. wearing-off phenomena and dyskinesias. Levodopa (after conversion to dopamine) stimulates D1 D2 receptors, whereas presently available agonists act on receptors. Therefore, might be a potential target
springer.com
sci-hub.se 参考文章(62)
H. Ehringer, O. Hornykiewicz, [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Journal of Molecular Medicine. ,vol. 38, pp. 1236- 1239 ,(1960) , 10.1007/BF01485901
G. Andringa, R.J. Vermeulen, B. Drukarch, J.C. Stoof, A.R. Cools, dopamine receptor subtypes as targets for the pharmacotherapy of parkinson's disease Advances in pharmacology. ,vol. 42, pp. 792- 795 ,(1998) , 10.1016/S1054-3589(08)60866-2
G.J. Fici, H. Wu, P.F. Von Voigtlander, V.H. Sethy, D1 dopamine receptor activity of anti-Parkinsonian drugs Life Sciences. ,vol. 60, pp. 1597- 1603 ,(1997) , 10.1016/S0024-3205(97)00126-4
George S. Robertson, Harold A. Robertson, Synergistic effects of D1 and D2 dopamine agonists on turning behaviour in rats Brain Research. ,vol. 384, pp. 387- 390 ,(1986) , 10.1016/0006-8993(86)91178-9
R. Jeroen Vermeulen, Benjamin Drukarch, M.C. Rob Sahadat, Cornelis Goosen, Erik Ch. Wolters, Johannes C. Stoof, The selective dopamine D1 receptor agonist, SKF 81297, stimulates motor behaviour of MPTP-lesioned monkeys. European Journal of Pharmacology. ,vol. 235, pp. 143- 147 ,(1993) , 10.1016/0014-2999(93)90834-5
D. B. Calne, P. F. Teychenne, L. E. Claveria, R. Eastman, J. K. Greenacre, A. Petrie, Bromocriptine in Parkinsonism. BMJ. ,vol. 4, pp. 442- 444 ,(1974) , 10.1136/BMJ.4.5942.442
A. Braun, G. Fabbrini, M. M. Mouradian, C. Serrati, P. Barone, T. N. Chase, Selective D-1 dopamine receptor agonist treatment of Parkinson's disease. Journal of Neural Transmission. ,vol. 68, pp. 41- 50 ,(1987) , 10.1007/BF01244638
R. J. Vermeulen, B. Drukarch, M. C. R. Sahadat, C. Goosen, E. C. Wolters, J. C. Stoof, The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys. Movement Disorders. ,vol. 9, pp. 664- 672 ,(1994) , 10.1002/MDS.870090613
Jørn Arnt, John Hyttel, Jens Perregaard, Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats. European Journal of Pharmacology. ,vol. 133, pp. 137- 145 ,(1987) , 10.1016/0014-2999(87)90144-0
M. Nomoto, P. Jenner, C.D. Marsden, The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset Neuroscience Letters. ,vol. 93, pp. 275- 280 ,(1988) , 10.1016/0304-3940(88)90095-X